Essex Investment Management Co. LLC Has $2.65 Million Stock Holdings in MediWound Ltd. (NASDAQ:MDWD)

Essex Investment Management Co. LLC increased its position in MediWound Ltd. (NASDAQ:MDWD - Free Report) by 30.7% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 148,949 shares of the biopharmaceutical company's stock after purchasing an additional 35,012 shares during the period. Essex Investment Management Co. LLC owned about 1.38% of MediWound worth $2,651,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. MetLife Investment Management LLC acquired a new stake in shares of MediWound during the third quarter worth approximately $89,000. Investor AB purchased a new stake in shares of MediWound during the third quarter worth $15,750,000. Point72 Asset Management L.P. acquired a new stake in MediWound during the third quarter valued at $212,000. State Street Corp boosted its position in MediWound by 219.6% during the third quarter. State Street Corp now owns 66,258 shares of the biopharmaceutical company's stock valued at $1,197,000 after purchasing an additional 45,529 shares during the last quarter. Finally, Barclays PLC raised its stake in shares of MediWound by 311.3% during the 3rd quarter. Barclays PLC now owns 11,163 shares of the biopharmaceutical company's stock worth $202,000 after purchasing an additional 8,449 shares in the last quarter. 46.83% of the stock is currently owned by hedge funds and other institutional investors.

MediWound Stock Performance

Shares of MediWound stock traded up $0.39 during trading on Thursday, reaching $18.23. The company's stock had a trading volume of 97,244 shares, compared to its average volume of 89,694. MediWound Ltd. has a one year low of $12.78 and a one year high of $24.00. The firm has a market cap of $196.63 million, a price-to-earnings ratio of -6.29 and a beta of 0.82. The business's fifty day moving average price is $18.02 and its 200-day moving average price is $17.61.

Remove Ads

Analyst Ratings Changes

A number of equities research analysts recently issued reports on MDWD shares. HC Wainwright reiterated a "buy" rating and issued a $25.00 price objective on shares of MediWound in a report on Friday, January 10th. Craig Hallum began coverage on shares of MediWound in a research report on Friday, February 28th. They issued a "buy" rating and a $39.00 price target on the stock.

MediWound Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.